I've been sitting with this question for a few days now.
Most "AI for science" talk is still about faster lit reviews, cleaner code, tidier plots. Useful, but not new. What Anthropic just showed with Mythos-class models feels like something else.
In internal tests, Mythos 5 sped up drug design roughly 10x. Nine of fourteen protein targets it worked on produced strong candidates. And in blind comparisons, researchers preferred its molecular biology hypotheses over Opus-class models about 80% of the time.
But the genomics result is the one that actually stopped me mid-scroll. Mythos 5 pulled together single-cell data across 138 species, designed its own modeling approach, trained something 100x smaller than the comparison system — and that smaller model beat a result published in Science. Not "helped write it." Ran the whole thing: hypothesis, method, execution, evaluation.
As someone who's spent years training models, writing papers, and knowing exactly how much grinding sits behind every "novel" result — that one made me pause.
And notice: access is still tightly locked down. Project Glasswing, a small biology trusted-access program coming soon. That's not a company hyping a headline. That's a company that knows it's holding something it isn't fully sure how to hand out yet.
So is this "new science"? Not a new field, not new axioms. Not yet. But autonomously forming hypotheses and beating specialists at their own game — that's not incremental anymore.
I don't have a clean answer. I just know the line between "tool" and "collaborator" moved this week, and I'm not sure my mental model of research has caught up.
Where do you draw that line?
أخبار
Beyond Generalist Models: Why Vertical ML and Computer Vision Are Winning in 2026
visibility
39
لا توجد تعليقات بعد. كن أول من يعلّق!